Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2004-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.48.10.4027-4032.2004PMID 15388472PMCID PMC521909
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oxazolidinones

  2012cited by this paper
• Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates.

  2004cited by this paper
• Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor.

  2004cited by this paper
• Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase.

  2004cited by this paper
• Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.

  2004cited by this paper
• Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor.

  2003cited by this paper
• Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor.

  2003cited by this paper
• Antipneumococcal and Antistaphylococcal Activities of Ranbezolid (RBX 7644), a New Oxazolidinone, Compared to Those of Other Agents

  2003cited by this paper
• Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials.

  2003cited by this paper
• In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

  2001cited by this paper
• Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

  2000cited by this paper
• Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

  2000cited by this paper
• Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections

  2000cited by this paper
• Fluoroquinolone resistance in Streptococcus pneumoniae.

  1999cited by this paper
• Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 Oral Antimicrobial Agents Based on Pharmacodynamic Parameters: 1997 U.S. Surveillance Study

  1999cited by this paper
• Fluoroquinolone resistance in Streptococcus pneumoniae.

  1999cited by this paper
• Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams

  1997cited by this paper
• Antibiotic-resistant pneumococci.

  1996cited by this paper
• MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci

  1996cited by this paper
• Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci.

  1995cited by this paper
• Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology

  1994cited by this paper
• Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

  1994cited by this paper
• Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

  1994cited by this paper
• Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.

  1993cited by this paper
• Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin

  1992cited by this paper
• Antimicrobial resistance in Streptococcus pneumoniae: an overview.

  1992cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically

  1990cited by this paper
• Biologic effects of dental materials. 3. Toxicity and antimicrobial effect of endodontic antiseptics in vitro.

  1973cited by this paper

• Advances in MRSA drug discovery: where are we and where do we need to be?

  2013cites this paper
• Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322

  2013cites this paper
• PEPTIDE DEFORMYLASE AS A NOVEL TARGET OF ANTIMICROBIALS

  2012cites this paper
• Multidrug-Resistant Streptococcus pneumoniae Infections

  2012cites this paper
• Pharmacokinetics and Unexpected Safety Issues of LBM415, a Novel Oral Peptide Deformylase Inhibitor

  2011cites this paper
• Fmt Bypass in Pseudomonas aeruginosa Causes Induction of MexXY Efflux Pump Expression

  2009cites this paper
• Characterization of the Peptide Deformylase Inhibitor LBM 415 in Murine Infection Models

  2009cites this paper
• Peptide deformylase – a promising therapeutic target for tuberculosis and antibacterial drug discovery

  2009cites this paper
• In Vivo Characterization of the Peptide Deformylase Inhibitor LBM415 in Murine Infection Models

  2009cites this paper
• Drug forecast – the peptide deformylase inhibitors as antibacterial agents

  2007cites this paper
• Characterization of Peptide Deformylase 2 from B . cereus

  2007cites this paper
• Characterization of peptide deformylase2 from B. cereus.

  2007cites this paper
• Multistep Resistance Selection and Postantibiotic-Effect Studies of the Antipneumococcal Activity of LBM415 Compared to Other Agents

  2006cites this paper
• Peptide deformylase inhibitors.

  2006cites this paper
• Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).

  2006cites this paper
• Activity of LBM415 Compared to Those of 11 Other Agents against Haemophilus Species

  2006cites this paper
• The evolution of peptide deformylase as a target: contribution of biochemistry, genetics and genomics.

  2006cites this paper
• 1 MULTISTEP RESISTANCE SELECTION AND PAE STUDIES ON ANTIPNEUMOCOCCAL ACTIVITY OF LBM 415 COMPARED TO OTHER AGENTS

  2006cites this paper
• Therapeutic potential of peptide deformylase inhibitors

  2005cites this paper
• Evaluation of LBM 415 ( NVP PDF-713 ) , a Novel Peptide Deformylase Inhibitor , for Treatment of Experimental Mycoplasma pneumoniae Pneumonia

  2005cites this paper
• Peptide deformylase inhibitors: a survey of the patent literature

  2005cites this paper
• Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria.

  2005cites this paper
• Bacterial Peptide deformylase inhibitors: a new class of antibacterial agents.

  2005cites this paper
• Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan.

  2005cites this paper
• Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia

  2005cites this paper
• New advances in antibiotic development and discovery

  2005influential citation
• Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance

  2005cites this paper